PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics

被引：0
|
作者：
Powles, T. B. [1 ]
van der Heijden, M. S. [2 ]
Balar, A. V. [3 ]
O'Donnell, P. [4 ]
Massard, C. [5 ]
Walker, J. [6 ]
Gupta, A. [7 ]
Angra, N. [7 ]
Cairns, J. [8 ]
Turriziani, B. [6 ]
Rebelatto, M. C. [7 ]
Scott, M. [6 ]
Wildsmith, S. [6 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands
[3] NYU, Dept Med, Perlmutter Canc Ctr, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[4] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[5] Gustave Roussy Canc Campus, DITEP, Villejuif, France
[6] AstraZeneca, Oncol R&D, Cambridge, England
[7] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca, Stat, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13P
引用
收藏
页码：S1421 / S1421
页数：1
相关论文
共 50 条
  • [31] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [32] Advanced or metastatic Urothelial Carcinoma New First-line Strategy established with PD-L1 Inhibitor
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [33] Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
    Bergmann, Sonja
    Coym, Anja
    Ott, Leonie
    Soave, Armin
    Rink, Michael
    Janning, Melanie
    Stoupiec, Malgorzata
    Coith, Cornelia
    Peine, Sven
    von Amsberg, Gunhild
    Pantel, Klaus
    Riethdorf, Sabine
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [34] Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma of the bladder
    Bergmann, Sonja
    Coym, Anja
    von Amsberg, Gunhild
    Janning, Melanie
    Soave, Armin
    Rink, Michael
    Pantel, Klaus
    Riethdorf, Sabine
    CANCER RESEARCH, 2019, 79 (13)
  • [35] PD-L1 expression in primary lesions vs metastatic sites and by demographics in advanced urothelial carcinoma samples
    Zajac, M.
    Boothman, A. M.
    Ben, Y.
    Gupta, A.
    Jin, X.
    Antal, J.
    Sharpe, A.
    Scott, M.
    Rebelatto, M.
    Walker, J.
    CANCER RESEARCH, 2017, 77
  • [36] Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
    Pinard, Christopher J.
    Hocker, Samuel E.
    Poon, Andrew C.
    Inkol, Jordon M.
    Matsuyama, Arata
    Wood, R. Darren
    Wood, Geoffrey A.
    Woods, J. Paul
    Mutsaers, Anthony J.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2022, 243
  • [37] Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma
    Campedel, L.
    Seisen, T.
    Cussenot, O.
    Comperat, E.
    Varinot, J.
    Roupret, M.
    Cancel-Tassin, G.
    PROGRES EN UROLOGIE, 2018, 28 (16): : 900 - 905
  • [38] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
  • [39] The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
    Powles, Thomas
    Walker, Jill
    Williams, J. Andrew
    Bellmunt, Joaquim
    CANCER TREATMENT REVIEWS, 2020, 82
  • [40] Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
    Niu, Mengke
    Liu, Yiming
    Yi, Ming
    Jiao, Dechao
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345